Cited by 150Blood Pressure and Hypertension StudiesLipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients: National Health and Nutrition Examination Surveys 1988–2010

Open access
Egan, Brent M., Li, Jiexiang, Qanungo, Suparna, Wolfman, Tamara E.·2013·Circulation

Abstract

Background—: Hypertension doubles coronary heart disease (CHD) risk. Treating hypertension only reduces CHD risk ≈25%. Treating hypercholesterolemia in hypertensive patients reduces residual CHD risk >35%. Methods and Results—: To assess progress in concurrent hypertension and hypercholesterolemia control, National Health and Nutrition Examination Surveys 1988 to 1994, 1999 to 2004, and 2005 to 2010 were analyzed. Hypertension was defined by blood pressure ≥140/≥90 mm Hg, current medication treatment, and 2-told hypertension status; blood pressure <140/<90 defined control. Hypercholesterolemia was defined by ATP III criteria based on 10-year CHD risk, low-density lipoprotein cholesterol (LDL-C), and non–high-density lipoprotein cholesterol; values below diagnostic thresholds defined control. Across surveys, 60.7% to 64.3% of hypertensives were hypercholesterolemic. From 1988 to 1994 to 2005 to 2010, control of LDL-C rose (9.2% [95% confidence interval (CI), 6.6%–11.9%] to 45.4% [95% CI, 42.6%–48.3%]), concomitant hypertension and LDL-C (5.0% [95% CI, 3.3%–6.7%] to 30.7% [95% CI, 27.9%–33.4%]), and combined hypertension, LDL-C, and non–high-density lipoprotein cholesterol (1.8% [95% CI, 0.4%–3.2%] to 26.9% [95% CI, 24.4%–29.5%]). By multivariable logistic regression, factors associated with concomitant hypertension, LDL-C, and non–high-density lipoprotein cholesterol control (odds ratio [95% CI]) were statin (10.7 [8.1–14.3]) and antihypertensive (3.32 [2.45–4.50]) medications, age (0.77 [0.69–0.88]/10-year increase), ≥2 healthcare visits/yr (1.90 [1.26-2.87]), black race (0.59 [0.44–0.80]), Hispanic ethnicity (0.62 [0.43–0.90]), cardiovascular disease (0.44 [0.34–0.56]), and diabetes mellitus (0.54 [0.42–0.70]). Conclusions—: Despite progress, opportunities for improving concomitant hypertension and hypercholesterolemia control persist. Prescribing antihypertensive and antihyperlipidemic medications to achieve treatment goals, especially for older, minority, diabetic, and cardiovascular disease patients, and accessing healthcare at least biannually could improve concurrent risk factor control and CHD prevention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.112.000500

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Approximately half of treated patients do not have adequate blood pressure or glycemic control.

    “Despite the widespread availability of effective treatments, approximately half of treated patients do not have adequate blood pressure (BP) or glycemic control [4,6,7].”

    From Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial (2017) · cites this paper as [6]

    The Results (page not provided) report that 66% of hypertensive patients were treated and 21.5% were treated but had uncontrolled blood pressure—about one-third of treated patients, not approximately half. The approximately half figure (46%) applies to all hypertensive patients, including untreated patients. The paper examines cholesterol control, not glycemic control. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Egan, B. M., Li, J., Qanungo, S., & Wolfman, T. E.
Affiliations
Medical University of South Carolina (US)
Venue
Circulation
Published
2013-07-02
Volume
128
Issue
1
Pages
29-41
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1963941738
Cited by
150
References
51
Citations by year
2026: 8 · 2025: 10 · 2024: 7 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 8 · 2019: 15 · 2018: 6 · 2017: 12 · 2016: 13 · 2015: 18 · 2014: 22 · 2013: 4
FWCI
12.90
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R34HL105880, R01HL091841, HL091841, HL105880)
  • National Institute of Neurological Disorders and Stroke (NS058728, U01NS058728)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
hypertension, hypercholesterolemia, blood pressure control, LDL cholesterol control, non-HDL cholesterol, coronary heart disease risk, statin therapy, antihypertensive drugs, health care utilization, cardiovascular risk management, comorbidities, lipid-lowering therapy, antihypertensive therapy, LDL/HDL ratio
MeSH terms
Adult, Aged, Blood Pressure, Cholesterol, Coronary Artery Disease, Female, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Nutrition Surveys, Risk Factors, United States, Comorbidity, Multivariate Analysis, Logistic Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review